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Aims: Excessive production of nitric oxide (NO) and reactive oxygen species (ROS) in sepsis modulates differ-
ent cell functions. Since the sepsis severity is associated with the degree of platelet activation, we decided to
investigate the role of systemic generation of NO and ROS in modulating the platelet adhesion of lipopolysac-
charide (LPS)-treated rats.
Main methods: Platelet adhesion was evaluated using ﬁbrinogen-coated 96-well microtiter plates. Cyclic GMP
levels were measured using enzyme immunoassay kit.
Key ﬁndings: Treatment of rats with LPS signiﬁcantly increased spontaneous platelet adhesion, but reduced
the thrombin-activated platelet adhesion when compared with control rats. Chronic treatment of rats with
the NO synthase inhibitor L-NAME (20 mg/rat/day, 7 days) prior to LPS injection normalized the increased
adhesion in non-activated platelets, but failed to affect the adhesion in thrombin-activated platelets. The
cGMP levels were modiﬁed neither in non-activated nor in thrombin-activated platelets of LPS-treated rats
when compared with control rats. The incubation of non-activated platelets with the O2
− scavenger PEG-SOD
reversed the stimulatory effect of LPS on spontaneous adhesion, but had no effect in stimulated-platelet adhesion
of non-treated or LPS-treated groups. Moreover, pretreatment of rats with the antioxidant N-acetylcysteine
(NAC; 150 mg/kg) prevented the increase of non-activated platelet adhesion, and signiﬁcantly reduced the
inhibitory effect of LPS on thrombin-stimulated adhesion.
Signiﬁcance: Our ﬁndings suggest that in LPS-treated rats, NO plays an important modulatory role only in non-
stimulated platelet adhesion through cGMP-independent mechanisms, while ROS, directly or by affecting the
redox state of the animals, modulates both non-activated and thrombin-activated platelet adhesion.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Platelet activation has a pivotal role in the primary hemostatic event
in the cessation of bleeding in damaged blood vessel and it is the
primary thrombotic event to precipitate ischemic complications. The
activation process occurs through inside-out and outside-in signaling.
Inside-out signaling occurs in response to cellular agonist such as
thrombin and outside-in signaling is an integrin-mediated cellular
event (Lévi-Toledano, 1999). The αIIbβ3 is an important integrin to
mediate outside-in signaling and is involved in both platelet adhesion
and aggregation. In unstimulated platelets, theαIIbβ3 integrin is an in-
active form, and has low afﬁnity for soluble or immobilized ﬁbrinogen
and von Willebrand factor (Savage et al., 1992). When platelets aregy, Faculty of Medical Sciences,
nas (SP), Brazil. Tel.: +55 19
des@uol.com.br
evier OA license.stimulated by different agonists, the αIIbβ3 is converted from low- to
high-afﬁnity receptor. Outside-in αIIbβ3 signaling determines the ex-
tent of platelet aggregation and spreading (Shattil, 2005).
In addition to regulate primary hemostasis, previous works indi-
cate that activated platelets contribute to inﬂammatory processes, in-
cluding sepsis. Accordingly, the ﬁrst signals in sepsis are the reduction
of leukocyte and platelet number in peripheral blood. In addition, the
severity of sepsis correlates to platelet activation state (Russwurm
et al., 2002). Lipopolysaccharide (LPS) is a component of the outer
membrane of Gram-negative bacteria and has a crucial role in induc-
ing Gram-negative sepsis. LPS interacts with a number of cell types
such as endothelial cells, macrophages, leukocytes and platelets,
causing the release of different substances including cytokines,
chemokines, reactive oxygen (ROS) and nitrogen species (RNS)
(McCuskey et al., 1996). These reactive species are important to mod-
ulate the cell function, and in combination with endogenous antioxi-
dant systems are crucial to the maintenance of the redox balance in
the organism (Valko et al., 2007).
The effects of LPS on platelet activity are quite conﬂicting. LPS ad-
ministration to mice or rats increases platelet adhesion to intestinal
venules (Katayama et al., 2000; Cerwinka et al., 2003). More recently,
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platelet aggregation, and to stimulate platelet secretion of dense
and alpha granule (Zhang et al., 2009). In contrast, LPS in vitro has
been shown to inhibit platelet aggregation induced by ionophore
A23187 and collagen (Saba et al., 1984; Sheu et al., 1998, 1999). In ad-
dition, LPS reduces Ca2+ mobilization and thromboxane A2 formation
in platelets, and augments the nitric oxide (NO)/cGMP levels (Sheu
et al., 1998, 1999).
As mentioned above, most of the studies have been carried out
using LPS in vitro and only few works investigated the in vivo effects
of LPS on platelet reactivity (Katayama et al., 2000; Cicala et al., 1997).
Data obtained with ex-vivo LPS-treated platelets are of potential in-
terest because it reﬂects the direct effect of LPS and the substances
generated during the progress of sepsis. In the present study our
hypothesis was that substances released in sepsis modulate the
platelet activity. Therefore, the objective of the present work was to
study the effects of intraperitoneal treatment of rats with LPS on ex-
vivo platelet adhesion to ﬁbrinogen. The modulatory role of ROS
and RNS in the platelet adhesion has also been investigated.
Materials and methods
Materials
Lipopolysaccharide from Escherichia coli (type 0111:B4), ﬁbrinogen
(fraction I from human plasma), thrombin, N-Acetylcysteine, polyethyl-
ene glycol-superoxide dismutase (PEG-SOD), Nω-nitro-L-argininemethyl
ester (L-NAME), phosphatase substrate (p-Nitrophenyl phosphate, sodi-
um), 3-Isobutyl-1-methylxanthine (IBMX) were purchased from Sigma
Chem. Co. (St. Louis, MO, USA). Cyclic GMP enzyme immunoassay (EIA)
kits were purchased from Cayman Co. (Ann Arbor, MI, USA).
Experimental protocol
The present study was approved by the Ethical Principles in Animal
Research adopted by the Brazilian College for Animal Experimentation
(COBEA). Male Wistar rats (250–320 g) were housed in temperature-
controlled rooms and received water and food ad libitum. Rats
were injected i.p. with saline (0.3 ml) or LPS (1 mg/kg), and at 2 h
to 48 h thereafter blood was collected. In a second experimental
group, N-acetylcysteine (NAC) was injected (150 mg/kg, i.p.) 30 min
after LPS or saline injection (Victor et al., 2003). Finally, in a third ex-
perimental group, rats were chronically treated with the NO synthase
inhibitor L-NAME (20 mg/rat/day) in the drinking water for 7 days
before LPS injection.
Washed platelet preparation
Ratswere anaesthetizedwith isoﬂurane and the bloodwas collected
from abdominal aorta in 1:9 (v/v) of ACD-C (12.4 mM sodium
citrate, 13 mM citric acid, 11 mM glucose). First, platelet-rich plasma
(PRP) was obtained by centrifugation of whole blood at 200 g for
15 min at room temperature. Five milliliters of PRP was added to 7 ml
of washing buffer (140 mMNaCl, 0.5 mMKCl, 12 mM trisodium citrate,
10 mM glucose, 12.5 mM saccharose, pH6), and centrifuged (800 g,
13 min). The pellet was resuspended in washing buffer, and the proce-
dure was repeated once. The platelets were gently suspended in Krebs
solution (118 mM NaCl, 25 mM NaHCO3, 1.2 mM KH2PO4, 1.7 mM
MgSO4, 5.6 mM glucose, pH 7.4). The platelet number was adjusted to
1.2×108platelets/ml in the presence of 1 mM CaCl2.
Platelet adhesion assay
Adhesion assay was carried out according to previous studies
(Bellavite et al., 1994; Marcondes et al., 2006). Brieﬂy, the 96-well
microtiter plates were coated (overnight at 4 °C) by adding 50 μlper well of human ﬁbrinogen (50 μg/ml). Before use, the wells were
washed twice with Krebs solution. The nonspeciﬁc adhesion was
blocked by incubation of wells with 1% BSA (1 h, 37 °C). At the end
of incubation, the plate was washed again, and platelet suspension
(50 μl containing 6×106 platelets) was added to each well. Platelet sus-
pension, in the absence or in the presence of thrombin (0.1–50 mU/ml),
was allowed to adhere to the wells for 30 min at 37 °C. In some
experimental protocols, platelets were pre-incubated with PEG-SOD
(30 U/ml, 5 min) prior to thrombin addition. Thereafter, the plates were
carefully washed twice with 200 μl/well of the Krebs solution to remove
unattached platelets. Adherent platelets were quantiﬁed through the
measurement of acid phosphatase activity. Thewells containing adherent
platelets were incubated with 150 μl/well of acid phosphatase substrate
solution (0.1 M citrate buffer pH 5.4, containing 5 mM p-nitrophenyl
phosphate and 0.1% Triton X-100) and after 1 h of incubation at
room temperature the reaction was stopped, and the color was devel-
oped by addition of 100 μl of 2 N NaOH. The p-nitrophenol produced
by the reactionwasmeasuredwith amicroplate reader at 405 nm (Spec-
traMax340,MolecularDevices, Sunnyvale, CA). The percentage of adher-
ent cells was calculated on the basis of a standard curve obtained with
known numbers of platelets. All the experiments were performed in
triplicates.
Tail-cuff pressure measurements
Tail-cuff pressure was evaluated before starting the chronic treat-
ment with L-NAME, and at the end of treatment, prior and after LPS
injection.
Cyclic GMP determination
Platelets (1.2×108platelets/ml) were incubated with the phos-
phodiesterase inhibitor 3-isobutyl-l-methylxanthine (IBMX, 2 mM)
for 15 min at room temperature. Next, non-activated or thrombin
(30 mU/ml)-activated platelets were incubated with Krebs solution
for 30 min. Some of these experiments were carried out in the pres-
ence of PEG-SOD (30 U/ml). The reaction was interrupted by the ad-
dition of cold acidiﬁed absolute ethanol to a ﬁnal concentration of
67% (v/v), and samples were vigorously agitated for 30 s. Cell samples
were then incubated on ice for 30 min before centrifuging at 4000 g
for 30 min at 4 °C. Supernatants were collected and retained and the
precipitates washed with 0.5 ml 67% (v/v) acidiﬁed ethanol before
centrifuging again at 14,000 g for 5 min at room temperature. Super-
natants from these washed samples were collected and added to the
ﬁrst supernatants collected and dried at 55–60 °C under a stream of
nitrogen in a water bath and stored at −20 °C until measurement of
cGMP. Cyclic GMP was measured using a kit from Cayman Chemical
Co. (Ann Arbor, MI, USA).
Statistical analysis
Data are expressed as means±SEM of N animals. The statistical
signiﬁcance between groups was determined by using one-way
ANOVA followed by the Tukey test. A p value of less than 0.05 was
considered statistically signiﬁcant.
Results
Effect of LPS administration in rats on platelet adhesion to ﬁbrinogen
Signiﬁcant platelet adhesion (6×106platelets/well) was observed
when non-activated platelets were kept on plates for 30 min (5.3±
0.2%). The adhesion was signiﬁcantly increased when platelets were
activated with 30 mU/ml of thrombin (50±5%; pb0.05).
Fig. 1A shows that adhesion of non-activated platelets was signif-
icantly increased at 2, 6 and 8 h after LPS injection when compared
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Fig. 2. Effect of the superoxide anion scavenger PEG-SOD on platelet adhesion of LPS-
treated rats. Rats were injected with saline or LPS (1 mg/kg, i.p.) and after 6 h the
blood was collected. Non-activated (6×106platelets/well) (panel A) or thrombin
(30 mU/ml)-activated platelets (panel B) were pre-incubated with PEG-SOD (30 U/ml)
and the adhesion was evaluated after 30 min. Results represent the mean±S.E.M. of
6–9 animals per group. ⁎Pb0.05 compared to the respective control of platelets not incu-
bated with PEG-SOD.
775A.L. Casarin et al. / Life Sciences 89 (2011) 773–778with the control rats (37%, 53% and 68% increase, respectively). At
48 h after LPS injection, the platelet adhesion returned to control
values.
In contrast to non-activated platelets, LPS injection signiﬁcantly
reduced thrombin (30 mU/ml)-stimulated platelet adhesion, as ob-
served at 6 and 8 h (62% and 52% reduction, respectively; Fig. 1B).
This inhibitory effect of thrombin-activated platelet adhesion by LPS
was maintained up to 48 h (28% reduction). The time-point of 6 h
was routinely selected for the further assays.
Effect of the superoxide anion scavenger PEG-SOD on platelet adhesion
Non-activated platelet adhesion (Fig. 2A) was signiﬁcantly inhib-
ited by incubation of control platelets with PEG-SOD (30 U/ml,
5 min). In addition, PEG-SOD reversed the stimulatory effect of LPS
(6 h) on non-activated platelet adhesion (Fig. 2A).
In contrast with the non-activated platelet adhesion, the inhibi-
tion of platelet adhesion by LPS (6 h) in thrombin-activated platelets
remained unchanged in the presence of PEG-SOD (30 U/ml, 5 min;
Fig. 2B).
Effect of NO synthase inhibitor L-NAME on platelet adhesion of
LPS-treated rats
In order to investigate the role of systemically NO formation in
platelet adhesion after LPS treatment, rats were treated with L-NAME
(20 mg/kg/day) in the drinking water for 7 days before LPS or saline
injection. Treatment with L-NAME increased by approximately 85%
the tail-cuff pressure in comparison with control group (98±3 and
181±8 mmHg for control and L-NAME, respectively; pb0.05). In
L-NAME-treated rats, injection of LPS (6 h) reduced by 15% the tail-
cuff pressure (155±4 mmHg, pb0.01), but it remained signiﬁcantly
elevated when compared to the control group.0
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Fig. 1. Platelet adhesion of LPS-treated rats. Rats were injected with saline or LPS
(1 mg/kg, i.p.) and after 2–48 h the blood was collected. Non-activated (panel A) and
thrombin-activated platelets (panel B) were allowed to adhere to the wells for
30 min at 37 °C. Results represent the mean±S.E.M. of 5–8 animals per group.
*Pb0.05 compared to the rats injected with saline.Treatment of ratswith L-NAMEalone caused a signiﬁcant increase of
non-activated platelet adhesion (Fig. 3A). However, in LPS-injected rats,
the increased adhesion was normalized by L-NAME treatment (Fig. 3A).
Treatment of rats with L-NAME alone did not signiﬁcantly affect
the thrombin-activated platelet adhesion (n=7; Fig. 3B). In addition,0
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Fig. 3. Effect of the chronic pretreatment of animals with NO synthase inhibitor
L-NAME on platelet adhesion of LPS-treated rats. The rats were treated with L-NAME
(20 mg/animal/day) in the drinking water for 7 days before LPS injection. The rats
were injected with LPS (1 mg/kg), and after 6 h circulating blood was collected. Non-
activated (panel A) and thrombin-activated platelets (panel B) were allowed to adhere
to the wells for 30 min at 37 °C. Results represent the mean±S.E.M. of 9–12 animals
per group. ⁎Pb0.05 compared to the rats not treated with L-NAME. #Pb0.05 compared
to the respective control of rats injected with saline.
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Fig. 5. Effect of the treatment of animals with the antioxidant N-acetylcysteine (NAC) on
platelet adhesion of LPS-injected rats. The animals were treated with NAC (150 mg/kg,
i.p.) 30 min after saline or LPS (1 mg/kg, i.p.) injection. The blood of control rats was
collected 2 h after NAC injection and 6 h after LPS exposition. Non-activated (panel A)
or thrombin (30 mU/ml)-activated platelets (panel B) were allowed to adhere to the
wells for 30 min at 37 °C. Results represent the mean±S.E.M. of 4–8 animals per group.
⁎Pb0.05 compared to the platelets of rats injected only with LPS. #Pb0.05 compared to
the respective control of rats injected with saline.
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was not modiﬁed by L-NAME treatment (Fig. 3B).
Cyclic GMP determination in platelets of LPS-treated rats
In non-activated platelets, the cGMP levels did not signiﬁcantly dif-
fer between control and LPS (6 h) groups (Fig. 4A). Incubation of plate-
lets with PEG-SOD (30 U/ml) modiﬁed the cGMP levels neither in the
absence nor in the presence of LPS treatment (Fig. 4A). In non-activated
platelets, L-NAME reduced the cGMP levels of both control and LPS-
treated groups (25% and 41% reduction, respectively; Fig. 4A).
In thrombin-activated platelets (Fig. 4B), the cGMP levels did not
signiﬁcantly differ between control and LPS (6 h) groups. Incubation
of platelets with PEG-SOD (30 U/ml) modiﬁed the cGMP levels nei-
ther in the absence nor in the presence of LPS treatment (Fig. 4B).
Treatment with L-NAME signiﬁcantly decreased the cGMP levels in
thrombin-activated platelets in LPS-treated rats (Fig. 4B).
As a positive control, platelets from control rats were incubated
with the NO donor sodium nitroprusside (SNP, 100 μM), and cGMP
measured. The cGMP levels increased from 1.7±0.07 in the absence
to 4.4±0.3 pmol/mL in the presence of SNP (N=4; pb0.01).
Effect of the antioxidant N-acetylcysteine (NAC) on platelet adhesion of
LPS-treated animals
Treatment of rats with NAC (150 mg/kg, i.p.) did not change the
adhesion of non-activated or thrombin-activated platelets (Fig. 5).
However, NAC treatment reversed the increased adhesion by LPS
(6 h) seen in non-activated platelets (Fig. 5A). Moreover, in thrombin-
activated platelets, the reduction of platelet adhesion by LPSwas largely
attenuated (pb0.01) by NAC treatment (Fig. 5B).0.0
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Fig. 4. cGMP levels in platelets of LPS-treated rats. Rats were treated with tap water
alone or L-NAME (20 mg/animal/day) in the drinking water for 7 days before saline
or LPS injection, and after 6 h the blood was collected. In some experiments, the plate-
lets of rats treated with tap water were also incubated with PEG-SOD (30 U/ml) for
5 min at room temperature. cGMP levels were determined in non-activated (panel A)
and thrombin (30 mU/ml)-activated platelets (panel B). Results represent the
mean±S.E.M. of 4–5 animals per group. ⁎Pb0.05 compared to the platelets of rats
injected with LPS but not treated with PEG-SOD.Discussion
This study clearly shows that treatment of rats with LPS stimulates
the non-activated platelet adhesion, but rather inhibits adhesion
when platelets are activated with thrombin. Our data are consistent
with the hypothesis that the stimulatory effect of LPS in non-activated
platelet is modulated by both ROS and NO generation, while the
inhibitory effect of LPS in thrombin-activated platelet adhesion reﬂects
only systemic formation of ROS.
It is well-established that LPS produces large amounts of ROS by
different cell types. Previous works have shown that Chlamydia
pneumoniae and Proteus mirabilis LPS induce an enhancement of ROS
production in platelets (Kälvegren et al., 2005; Zielinski et al., 2001;
Saluk-Juszczak et al., 2000). Consistent with these studies, our results
showed that incubation of non-activated platelets with PEG-SOD
restored the stimulatory effect of LPS, indicating that ROS such as O2−
take part in this effect. Superoxide anion (O2−) has been previously
shown to activate human platelets (Krötz et al., 2002; Salvemini et al.,
1989). NAC, an antioxidant widely used in studies of oxidative stress,
besides to be a ROS scavenger, increases the cellular content of glutathi-
one, and inhibits NADPH oxidase activity (Martinez-Losa et al., 2007;
Kitaoka et al., 2005; Ritter et al., 2004). NAC is able to inhibit different
LPS responses by reducing ROS generation and/or by increasing gluta-
thione production (Rota et al., 2002; Lin et al., 2006). In our study,
NAC reversed the stimulatory effect of LPS on non-activated adhesion,
indicating that this effect is mediated by increased production of
systemic ROS. Accordingly, the increased platelet adhesion to intestinal
venules was shown to be mediated by neutrophil-derived superoxide
(Cerwinka et al., 2003). Evidences show that ROS increases the
activation of ﬁbrinogen receptor (integrin αIIbβ3) on platelets (Walsh
et al., 2004; Lahav et al., 2002). The oxidation of outside domain of
this integrin leads to platelet activation (Essex, 2009; Walsh et al.,
2004; Yan and Smith, 2000), and the phosphorylation of β3, a funda-
mental step in outside-in integrin signal transduction, is inhibited by
NAC (Irani et al., 1998).
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the effects of LPS on non-activated platelet adhesion, rats were treated
chronically with L-NAME. This treatment markedly enhanced arterial
blood pressure, conﬁrming that NO production was largely inhibited.
As expected, L-NAME increased the adhesion of control platelets,
conﬁrming previous studies showing that NO inhibits platelet activation
(Walter and Gambaryan, 2009; Irwin et al., 2009; Marcondes et al.,
2006). However, the increased adhesion of non-activated platelet by
LPSwas reversed by L-NAME treatment. L-NAME is reported to indirectly
increase the O2− bioavailability by preventing its reaction with NO
leading to peroxynitrite (ONOO−) generation (Cuzzocrea et al., 2004).
Therefore, we suggest that ONOO− formation contributes to the stimula-
tory effect of LPS in non-activated platelet adhesion. This is consistent
with previous studies showing that ONOO− induces human platelet
aggregation, and increases both P-selectin expression and levels of
cytosolic Ca++ (Redondo et al., 2005; Brown et al., 1998; Moro et al.,
1994). Furthermore, endogenously formed ONOO− in platelets activates
cyclooxygenase-1 leading to an enhancement of TXA2 synthesis and
platelet activation (Schildknecht et al., 2008).
In contrast to the non-activated platelet adhesion, LPS treatment
rather inhibited thrombin-activated platelet adhesion. The binding
of ﬁbrinogen to its receptor in platelets corresponds to the initial
step of protein phosphorylation in spontaneous adhesion, while in ac-
tivated platelets this event is a result of several intracellular pathways
activation (Shattil et al., 1994). The intracellular signaling induced by
thrombin in rodents is mediated mostly by protease-activated
receptor-4 (PAR-4) (Brass, 2003). The activation of this receptor
leads to phospholipase C activation and consequently higher produc-
tion of inositol 1,4,5-triphosphate (IP3), which elevates Ca++ mobili-
zation, and diacylglycerol (DAG), which in turn activates protein
kinase C (PKC). The Ca2+ inﬂux with p38MAP kinase-mediated phos-
phorylation activates phospholipase A2 that hydrolyses membrane
phospholipids, enhancing the arachidonic acid availability and
thromboxane A2 synthesis, thus amplifying the platelet activation
(De Cristofaro and De Candia, 2003). This cascade of intracellular
signals is called inside-out, and is responsible for conversion of recep-
tor GP IIb/IIIa from the low afﬁnity to the high-afﬁnity state, impor-
tant step to the ﬁrm platelet adhesion and stabilization of platelet
aggregates (Shattil, 2005; Lévi-Toledano, 1999). Thus, the reduction
of activated platelet adhesion in rats exposed to LPS may be due to in-
hibition of the initial steps of platelet activation, causing a decrease in
the activation of ﬁbrinogen receptor. In fact, there are some works
showing that E. coli LPS inhibits the mobilization of intracellular
Ca++ and PKC activation in human platelets stimulated by collagen
and thrombin (Sheu et al., 1998, 1999; Morganti et al., 2010).
Chronic L-NAME treatment did not affect the activated-platelet
adhesion in any experimental condition, even at 6 h after LPS injection
where the cGMP levels were signiﬁcantly reduced. Recently, we showed
that pre-incubation of human platelets with LPS at concentrations up to
100 μg/ml does not increase the cGMP contents above basal levels
(Morganti et al., 2010). Therefore, as opposed to non-activated platelets,
we suggest that NO does not contribute to the inhibitory effect of LPS in
thrombin-activated platelet adhesion. On the other hand, NAC treatment
signiﬁcantly restored the inhibitory effect of LPS in thrombin-activated
platelet adhesion. Results from previous studies support the hypothesis
that NAC increases the glutathione redox status, preventing tissue
damage by excessive ROS formation (Kamboj et al., 2010; Saini-Chohan
and Dhalla, 2009; Wang et al., 2009). In different models of sepsis, NAC
has protective effects by reducing proinﬂammatory cytokine production
(Senoglu et al., 2008), improving the redox state of macrophages and
lymphocytes (Victor et al., 2003) and preventing lung redox imbalance
and ONOO- generation (Carbonell et al., 2007; Ozdulger et al., 2003).
Therefore, our results indicate that oxidative stress plays an important
role in thrombin−activated platelet adhesion of LPS-treated rats.
Furthermore, our ﬁndings that PEG-SOD did not modify the inhibitory
effect of LPS in thrombin-activated platelet adhesion rule out thatendogenous formation of ROS in platelets itself contribute to this inhibi-
tory effect of LPS.
Conclusion
Treatment of rats with LPS has ambiguous effect on platelet adhe-
sion to ﬁbrinogen, since it increases the non-activated platelet adhe-
sion and reduces activated-platelet adhesion. NO modulates the
stimulatory effect of LPS on non-activated platelet adhesion through
GMPc-independent mechanisms, but it does not take part on the in-
hibitory effect of LPS on thrombin-activated platelet adhesion. The
generation of ROS in the LPS-treated rats plays an important role in
both non-activated and activated-platelet adhesion.
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